Press Releases

Date Title and Summary Additional Formats
Toggle Summary Evoke Accelerates New Drug Application Process by Engaging Regulatory Experts
NDA Preparation Initiates as EVK-001 Nears Phase 3 Study Completion
View HTML
Toggle Summary Evoke Advances Commercial Preparations for EVK-001 with inVentiv Agreement
SOLANA BEACH, Calif. , July 07, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), today announced that it has entered into a master service agreement with inVentiv Commercial Services LLC ("inVentiv") in connection with Evoke's preparation for commercial activities for EVK-001, its lead
View HTML
Toggle Summary Evoke Advances Commercial Preparations for EVK-001 with inVentiv Agreement
SOLANA BEACH, Calif., July 07, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), today announced that it has entered into a master service agreement with inVentiv Commercial Services LLC ("inVentiv") in connection with Evoke's preparation for commercial activities for EVK-001, its lead
View HTML
Toggle Summary Evoke Announces Timing of Phase 3 Results from its Recently Fully Enrolled Pivotal Clinical Trial of EVK-001
SOLANA BEACH, Calif., May 03, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK) today announced that it expects to provide top line data results from its pivotal Phase 3 clinical trial of EVK-001 in women with symptoms associated with diabetic gastroparesis early in the third quarter of
View HTML
Toggle Summary Evoke Completes Phase 3 Clinical Trial of EVK-001 in Women with Symptoms Associated with Diabetic Gastroparesis
205 subjects complete the study
View HTML
Toggle Summary Evoke Enters Exclusive Commercial Supply Agreement for Active Pharmaceutical Ingredient in EVK-001
SOLANA BEACH, Calif., May 19, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), today announced that it has signed an exclusive commercial supply agreement with COSMA S.p.A. for the active pharmaceutical ingredient (API) in its product candidate EVK-001.
View HTML
Toggle Summary Evoke Nears Completion of Phase 3 Clinical Trial Enrollment and Secures Extension to Credit Facility
186 of 200 Subjects Enrolled in Phase 3 Clinical Trial of EVK-001
View HTML
Toggle Summary Evoke Nears Completion of Phase 3 Clinical Trial Enrollment and Secures Extension to Credit Facility
186 of 200 Subjects Enrolled in Phase 3 Clinical Trial of EVK-001
View HTML
Toggle Summary Evoke Pharma Achieves Significant Manufacturing Milestone With Successful Completion of Commercial Scale Production of EVK-001
Manufacturing Program Includes Three Year Registration Stability Data
View HTML
Toggle Summary Evoke Pharma Announces $10 Million Registered Direct Offering Priced At-The-Market
SOLANA BEACH, Calif., July 29, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK) ("Evoke Pharma" or "the Company"), today announced that it has entered into definitive agreements with institutional investors for an offering of shares of common stock with gross proceeds of approximately $10
View HTML